EUVIMEDEUVIMED entdecken
Crossref

Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma

Toko Machida, Kaname Sakuma, Nobukazu Fuwa, Akira Tanaka

Anticancer Research · 2024

DOI: 10.21873/anticanres.16894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Toko Machida und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral & Maxillofacial Surgery, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan; machida@ngt.nd…. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Immune checkpoint inhibitors are highly effective for treating recurrent and metastatic head and neck cancers. However, they require systemic administration and are associated with immune-related adverse events (irAEs). Reducing therapeutic antibody doses to prevent irAEs is challenging. MATERIALS AND METHODS: Mouse buccal mucosa squamous cell carcinoma cells (Sq-1979) were transplanted into the backs of mice to induce tumors. The antitumor efficacy and tumor immunohistological environment in tumor-bearing mice were compared after administering a standard dose of programmed death-ligand 1 (PD-L1) antibodies systemically (200 mg/body) or 1/10th of the standard dose (20 mg/body) directly to tumors. Mice received four doses of antibody administered in 3-day intervals. Tumor reduction rates and antitumor efficacies were evaluated 21 days after initiating treatment. CD8+T cell counts and PD-L1, PD-1, perforin, and granzyme B levels; CD25 and Foxp3 expression levels; and tumor Tregs were assessed in the resected subcutaneous tumors. RESULTS: The antitumor efficacies in the local low-dose and systemic standard-dose groups were compared with that of the control group. The efficacies of the two treatment groups were similar, and both treatment groups revealed significant antitumor effects compared to the control group. Perforin and granzyme B levels were higher in the local low-dose group (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellMouth NeoplasmsHead and Neck NeoplasmsAnimalsMiceSquamous Cell Carcinoma of Head and NeckB7-H1 AntigenGranzymesPerforin

Stichwörter der Autor:innen

Granzymesbuccal mucosaimmune checkpoint inhibitorsimmune-related adverse eventslow-dose topical administrationoral cancer cell lineperforinprogrammed cell death ligand 1 antibodysquamous cell carcinoma

Substanzen

B7-H1 AntigenGranzymesPerforin

Autor:innen und Institutionen

  • Department of Oral & Maxillofacial Surgery, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan; machida@ngt.ndu.ac.jp.
  • Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Japan.
  • Oral and Maxillofacial Surgery, The Nippon Dental University Niigata Hospital, Niigata, Japan.
  • Department of Radiation Oncology, Central Japan International Medical Center, Minokamo, Japan.
  • Department of Oral & Maxillofacial Surgery, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan.

Zitieren

APA

Machida, T., Sakuma, K., Fuwa, N., & Tanaka, A. (2024). Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.16894

Vancouver

Machida T, Sakuma K, Fuwa N, Tanaka A. Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.16894

BibTeX
@article{Machida2024,
  author = {Machida, Toko and Sakuma, Kaname and Fuwa, Nobukazu and Tanaka, Akira},
  title = {Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16894}
}
Kostenlos starten →